ORAI1 and COVID-19: As innate immune cell over-activation, an exacerbated inflammatory response and thrombosis were linked with adverse COVID-19 outcome, ORAI1 could potentially play a role in this over-exuberant immune response, thrombotic state and adverse outcome in cases with serious symptoms and therefore could be a promising therapeutic target for COVID-19.